Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
Global steroid-corticosteroids market was valued at USD 4.65 billion in 2024. The market is projected to grow from USD 4.84 billion in 2025 to USD 6.04 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 3.9% during the forecast period.
Steroid-corticosteroids are a class of steroid hormones that are produced in the adrenal cortex of vertebrates, as well as the synthetic analogues of these hormones. They play a critical role in a wide range of physiological processes, including the regulation of inflammation, immune response, metabolism, and stress. Their potent anti-inflammatory and immunosuppressive properties make them indispensable in treating conditions such as asthma, rheumatoid arthritis, and various skin disorders.
The market growth is primarily driven by the rising global prevalence of chronic inflammatory and autoimmune diseases. Additionally, the increasing availability of these drugs in diverse formulations, including creams and injections, broadens their therapeutic application. The competitive landscape is concentrated, with Sumitomo leading the market with a revenue share exceeding 17%. Other key players, such as Pfizer and Novartis, maintain significant market presence through extensive product portfolios and ongoing research into advanced delivery systems to improve efficacy and patient compliance.
Rising Prevalence of Chronic Inflammatory Diseases
The global steroid-corticosteroids market is primarily driven by the increasing incidence and prevalence of chronic inflammatory and autoimmune diseases. Conditions such as rheumatoid arthritis, asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, and various dermatological conditions require long-term management, for which corticosteroids are a foundational therapy. The global aging population is more susceptible to these chronic conditions, thereby sustaining consistent demand for these potent anti-inflammatory agents. The World Health Organization highlights the growing burden of chronic diseases as a major public health challenge, which directly correlates with market growth.
Expansion in Generic Drug Production
The widespread availability of generic corticosteroid formulations has significantly improved patient access and affordability, acting as a major market driver. As patents for key brand-name corticosteroids have expired, numerous pharmaceutical companies have entered the market with cost-effective alternatives. This has been particularly impactful in emerging economies, where healthcare budgets are constrained. Generic competition has also spurred price competitiveness, making treatment regimens more accessible to a larger patient pool and driving volume-based market growth.
➤ The global corticosteroids market is projected to witness steady growth, with estimates suggesting a market size exceeding $5 billion, propelled by the factors of disease burden and drug accessibility.
Furthermore, advancements in drug delivery systems represent a significant driver. The development of targeted delivery mechanisms, such as inhalers for asthma, topical formulations for skin conditions, and intra-articular injections for joint diseases, has improved the efficacy and reduced the systemic side effects of corticosteroids. This has enhanced patient compliance and expanded the therapeutic applications of these drugs, supporting market expansion.
MARKET CHALLENGES
Stringent Regulatory Scrutiny and Side Effect Profile
Corticosteroids are potent drugs with a well-documented and significant risk profile for serious side effects, especially with long-term use. These include osteoporosis, diabetes, hypertension, cataracts, adrenal suppression, and increased susceptibility to infections. This necessitates stringent regulatory oversight and complex risk management strategies for pharmaceutical companies. The regulatory approval process for new formulations or indications is often prolonged and costly due to the need for extensive safety data, acting as a barrier to market entry and innovation.
Other Challenges
Patent Expirations and Price Erosion
While genericization drives volume, it presents a major challenge for originator companies through significant price erosion and loss of market share. The revenue generated from blockbuster corticosteroid drugs declines sharply post-patent expiry, challenging the profitability of innovator firms and potentially reducing incentives for extensive research and development into new corticosteroid entities.
Growing Preference for Biologics
In several therapeutic areas, such as rheumatology and dermatology, there is a growing clinical preference for biologic drugs over traditional corticosteroids for long-term management. Biologics often offer targeted action with a different side effect profile. This trend poses a competitive challenge, as corticosteroids may be increasingly used as a bridge therapy or for acute flares rather than as first-line long-term treatment, potentially curbing market growth.
Growing Awareness and Fear of Adverse Effects
Increased patient and physician awareness of the potential severe adverse effects associated with prolonged corticosteroid use is a significant market restraint. This awareness is leading to more cautious prescribing practices, with clinicians striving to use the lowest effective dose for the shortest possible duration ("steroid-sparing" regimens). In some cases, patients may refuse or be non-adherent to prescribed corticosteroid therapy due to fear of side effects, which can limit market growth despite clinical need.
Supply Chain Vulnerabilities for Raw Materials
The production of corticosteroids is dependent on a complex global supply chain for active pharmaceutical ingredients (APIs). Disruptions in this supply chain, as witnessed during global events like the COVID-19 pandemic, can lead to shortages and price volatility. Many steroid APIs are sourced from a limited number of manufacturers, predominantly in Asia, creating a vulnerability that can restrain consistent market supply and stability.
Development of Novel Formulations and Drug Delivery Systems
There is a substantial opportunity for growth through the innovation of novel corticosteroid formulations that minimize systemic exposure and target specific tissues. Technologies such as nanoparticle-based delivery, liposomal encapsulation, and sustained-release implants are being explored to enhance localized efficacy while reducing off-target side effects. These advanced formulations can open new therapeutic avenues and justify premium pricing, driving market value.
Expansion in Emerging Markets
Emerging economies in Asia-Pacific, Latin America, and Africa present significant growth opportunities. Rising healthcare expenditure, improving diagnostic capabilities, growing awareness of inflammatory diseases, and expanding access to healthcare in these regions are expected to drive demand. Local manufacturing of generic corticosteroids is also increasing, making treatments more affordable and accessible to larger populations, thereby expanding the total addressable market.
Increasing Application in New Therapeutic Areas
Research continues to explore the efficacy of corticosteroids in new indications, such as for the management of severe COVID-19 symptoms (as evidenced by the RECOVERY trial), certain neurological conditions, and oncology support care (e.g., managing inflammation from immunotherapy). The approval of corticosteroids for new, high-burden indications can create significant new revenue streams and fuel market growth beyond traditional applications.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Cream formulations represent a leading therapeutic format due to their widespread use in treating common dermatological conditions such as eczema and psoriasis, offering non-invasive application and direct targeted relief. The demand is further bolstered by the high prevalence of skin disorders and the preference for topical treatments among both patients and physicians for managing localized inflammation and allergic reactions effectively. |
| By Application |
|
Hospital applications constitute a dominant segment, driven by the extensive use of corticosteroid injections and systemic formulations for managing severe inflammatory and autoimmune conditions, post-surgical care, and critical care scenarios. The advanced infrastructure of hospitals supports the administration of potent formulations, making them a central hub for treating complex cases that require close monitoring and specialized healthcare expertise. |
| By End User |
|
Hospitals & Clinics remain the primary end-user segment, leveraging their critical role in diagnosis, treatment initiation, and management of chronic conditions requiring corticosteroid therapy. This segment benefits from established procurement channels, bulk purchasing power, and the necessity to handle a wide spectrum of therapeutic needs, from emergency interventions to long-term patient care plans, ensuring consistent and high-volume demand. |
| By Route of Administration |
|
Topical administration is a leading segment due to its extensive application in dermatology and preference for localized treatment with minimized systemic side effects, making it a first-line option for many inflammatory skin conditions. The convenience and safety profile of topical corticosteroids support robust patient compliance and drive significant market traction, particularly for over-the-counter and prescribed creams and ointments used in routine clinical practice. |
| By Therapeutic Area |
|
Dermatology emerges as the foremost therapeutic area, driven by the high global burden of inflammatory skin diseases and the established efficacy of corticosteroids in managing conditions like atopic dermatitis and contact dermatitis. The segment's growth is underpinned by continuous product innovations, patient awareness, and the expanding use of combination therapies that enhance treatment outcomes for a broad patient population seeking relief from chronic skin ailments. |
A market characterized by established pharmaceutical giants and strategic generic competition
The global Steroid-Corticosteroids market is dominated by a handful of major multinational pharmaceutical corporations, with Sumitomo holding a commanding leadership position. As the largest production manufacturer, Sumitomo's revenue accounts for over 17% of the global market. This is followed closely by industry titans Pfizer and Novartis, which leverage their extensive research and development capabilities, vast distribution networks, and strong brand recognition to maintain significant market shares. These leading players compete intensely on the basis of product portfolio diversification, covering various formulations like creams and injections, and their ability to secure regulatory approvals across different regions. The competitive dynamics are further shaped by ongoing investments in clinical trials for new therapeutic applications and lifecycle management of existing products.
Beyond the top-tier leaders, the market includes several other significant players that hold notable positions through specialized expertise and regional strength. Companies such as Merck, Sanofi, and Johnson & Johnson are key competitors with substantial product offerings. Furthermore, the landscape is populated by major generic manufacturers like Cipla, which compete effectively on price, particularly in cost-sensitive markets. Other important contributors include GlaxoSmithKline (GSK) and AstraZeneca, which apply their broad pharmaceutical experience to this segment. The market also features companies focusing on specific niches or regional dominance, ensuring a competitive environment that balances innovation with cost-effective production.
List of Key Steroid-Corticosteroids Companies ProfiledSumitomo
Merck
Johnson and Johnson
AstraZeneca
Cipla
Bayer
Teva Pharmaceutical Industries
Mylan N.V.
Lupin Limited
Hikma Pharmaceuticals
Sun Pharmaceutical Industries
The global Steroid-Corticosteroids market is on a trajectory of consistent growth, with its value projected to increase from US$ 4649 million in 2024 to US$ 6037 million by 2031, representing a compound annual growth rate (CAGR) of 3.9%. This steady expansion is primarily fueled by the persistent and growing demand for these hormones across various therapeutic areas. Steroid-Corticosteroids, both natural hormones produced in the adrenal cortex and their synthetic analogues, are critical in managing a wide range of inflammatory and autoimmune conditions. The increasing global prevalence of such diseases ensures a stable and expanding customer base for market participants.
Other TrendsDominance of Cream Formulations and Hospital Applications
Market segmentation reveals clear preferences in product type and application. Cream-based formulations hold a significant share of the market, favored for their efficacy in treating dermatological conditions. In terms of application, the hospital segment is the predominant end-user, accounting for the largest portion of market consumption. This is due to the need for controlled administration and monitoring of corticosteroid treatments for severe conditions. Clinics and other healthcare settings also contribute substantially to market volume, highlighting the widespread use of these drugs across the healthcare continuum.
The competitive landscape of the Steroid-Corticosteroids market is characterized by the presence of established pharmaceutical giants. Sumitomo stands as the largest production manufacturer, commanding a revenue share exceeding 17% of the global market. It is closely followed by other major players such as Pfizer and Novartis, with companies like Merck, Sanofi, and Johnson & Johnson also holding significant market positions. This concentration among a few key players indicates a mature market where innovation, production scale, and distribution networks are critical competitive factors. Geographically, the market is globally distributed, with significant activities across North America, Europe, and the rapidly growing markets in Asia.
Regional Analysis: Steroid-Corticosteroids MarketEurope
Europe represents a mature and significant market for steroid-corticosteroids, characterized by universal healthcare systems and high standards of medical care. Countries like Germany, the UK, and France are major contributors, with strong demand driven by an aging population susceptible to chronic inflammatory diseases. The market is heavily influenced by stringent EMA regulations that ensure drug safety and efficacy, while also promoting the use of cost-effective generic alternatives. There is a growing trend towards biosimilars and advanced topical formulations, supported by robust public healthcare funding. However, pricing pressures from government health authorities and a focus on pharmacovigilance regarding long-term corticosteroid use present ongoing challenges to market expansion.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for steroid-corticosteroids, fueled by improving healthcare access, rising disposable incomes, and increasing awareness of treatable chronic conditions. Large population bases in countries like China and India present immense potential, with growing diagnosis rates for asthma, dermatitis, and arthritis. The market is characterized by a high volume of generic drug production, making treatments more affordable. Expansion is further supported by government initiatives to improve rural healthcare infrastructure and the growing presence of multinational pharmaceutical companies establishing local manufacturing and distribution networks. Despite this growth, the market faces challenges such as regulatory heterogeneity and uneven quality standards across different countries.
South America
The steroid-corticosteroids market in South America is experiencing steady growth, though it is less developed compared to North America and Europe. Brazil and Argentina are the key markets, driven by increasing healthcare expenditure and a growing burden of respiratory and autoimmune diseases. Market dynamics are influenced by economic fluctuations and government efforts to expand public healthcare coverage. Access to modern medicines is improving in urban centers, but rural areas still face significant barriers. The region shows a strong preference for low-cost generic corticosteroids, and local manufacturing capabilities are expanding to meet domestic demand, though reliance on imports for more advanced formulations remains.
Middle East & Africa
The Middle East & Africa region presents a diverse and emerging market for corticosteroid products. The Gulf Cooperation Council (GCC) countries, with their high per capita healthcare spending, exhibit more advanced market characteristics, including adoption of newer therapies. In contrast, many African nations face challenges related to limited healthcare infrastructure, low awareness, and affordability issues. The market growth is primarily driven by the increasing prevalence of allergic and inflammatory conditions and gradual improvements in medical facilities. International aid and partnerships play a crucial role in drug accessibility in lower-income countries, but the market overall remains fragmented with significant unmet medical needs.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2031. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type (Cream, Injection, Others)
By application (Hospital, Clinic, Others)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Advanced delivery systems research
Formulation improvements and efficacy enhancements
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical companies
Healthcare providers
Research organizations
Investors and consultants
Policy makers
-> Global steroid-corticosteroids market was valued at USD 4.65 billion in 2024 and is projected to reach USD 6.04 billion by 2031.
-> Key players include Sumitomo (17% market share), Pfizer, Novartis, Merck, and Sanofi, among others.
-> Key growth drivers include rising prevalence of chronic inflammatory diseases and increasing therapeutic applications.
-> North America currently leads the market, while Asia-Pacific shows fastest growth potential.
-> Market is segmented by type into Cream, Injection, and Other formulations.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates